Daniel Payne , 2025-04-25 08:30:00
WASHINGTON — After November’s election, many of the lobbyists and lawyers representing the health care industry expected a second Trump term would be much like the first: opportunities for regulatory trims, concerns about budget cuts, and more governing via social media.
But less than 100 days into President Trump’s administration, far more sweeping changes are materializing for the health care industry, creating unprecedented challenges for companies and their Washington lobbyists.
The changes go well beyond unfavorable policies. At risk are the foundational government systems the organizations rely on to carry out their missions — whether that’s developing drugs, treating patients, insuring Americans or supporting people diagnosed with particular diseases.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
